What is Code Bio?
Founded in 2020 and headquartered in Philadelphia, PA, Code Bio is at the forefront of developing advanced gene therapy treatments. The company's proprietary non-viral gene delivery system offers a promising alternative to existing methods, aiming to address the limitations of current gene therapies, such as the inability to titrate dosage or address diseases caused by mutations in large genes. Code Bio's technology holds the potential to revolutionize treatment for patients suffering from severe genetic disorders, offering new hope for more effective and controllable therapeutic interventions.
How much funding has Code Bio raised?
Code Bio has raised a total of $85M across 2 funding rounds:
Angel/Seed
$10M
Series A
$75M
Angel/Seed (2021): $10M with participation from 4BIO Capital, New Enterprise Associates, JDRF T1D Fund, Takeda Pharmaceutical, CureDuchenne, and UPMC
Series A (2022): $75M led by CureDuchenne Ventures, UCB Ventures, Northpond Ventures, UPMC, Takeda, JDRF T1D Fund, Hatteras Venture Partners, 4BIO Capital, New Enterprise Associates, and Amgen Business Development
Key Investors in Code Bio
4BIO Capital
4BIO Capital is a venture capital firm specializing in life sciences, focusing on advanced therapies for significant unmet medical needs, including gene therapy.
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm that invests in companies across various stages, with a significant presence in the technology and healthcare sectors.
JDRF T1D Fund
The JDRF T1D Fund is a venture fund dedicated to accelerating treatments and cures for Type 1 Diabetes, investing in innovative therapies and disease modification.
What's next for Code Bio?
The substantial enterprise-level capital infusion, highlighted by the recent major strategic investment, positions Code Bio for significant growth and advancement in its research and development pipeline. This backing is expected to fuel the expansion of its therapeutic programs, facilitate clinical trial progression, and bolster its operational capabilities. With a focus on addressing unmet needs in genetic disease treatment, Code Bio is strategically poised to leverage this financing to further validate its platform and advance its pipeline towards potential commercialization, solidifying its role as a key player in the gene therapy landscape.
See full Code Bio company page
